
==== Front
Neurooncol Adv
Neurooncol Adv
noa
Neuro-Oncology Advances
2632-2498
Oxford University Press US

10.1093/noajnl/vdae090.113
vdae090.113
Final Category: Research Methods and Trial Design Considerations
AcademicSubjects/MED00300
AcademicSubjects/MED00310
RMTD-06 TREATMENT PATTERNS AND OUTCOMES OF HR+/HER2- BREAST CANCER WITH BRAIN METASTASES: A SINGLE-CENTER RETROSPECTIVE STUDY
Wei Zhu Jie University of Toronto, Toronto, Canada

Moravan Veronika Sunnybrook Health Sciences Centre, Toronto, Canada

Jerzak Katarzyna Sunnybrook Health Sciences Centre, Toronto, Canada

8 2024
02 8 2024
02 8 2024
6 Suppl 1 2024 SNO/ASCO CNS Metastases Conference i34i34
© The Author(s) 2024. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Abstract

BACKGROUND

Approximately 14% of patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) develop BrM during their lifetime, which is associated with a poor prognosis. We sought to assess the treatment patterns and outcomes of patients with HR+/HER2- breast cancer brain metastases (BCBrM).

METHODS

We conducted a single-centre retrospective cohort study of 204 patients (≥18 years of age) diagnosed with HR+/HER- mBC who were treated for BrM at the Sunnybrook Odette Cancer Centre between 2008 and 2018. We used descriptive statistics to summarize patient and treatment characteristics and Kaplan-Meier analyses for survival outcomes. The log-rank test was used to compare outcomes of patients with endocrine sensitive versus endocrine resistant disease.

RESULTS

Among 204 patients with HR+/HER2- BCBrM, the median age at BrM diagnosis was 56 years (range 31 – 93) and the median time between diagnosis of mBC to development of BrM was 15 months (interquartile range [IQR] 3 – 36 months). 135 (66.2%) patients had endocrine resistant disease, 53 (26%) patients had endocrine sensitive disease; endocrine sensitivity was not available for 16 patients (7.8%). The first line of systemic treatment following BrM diagnosis was chemotherapy for 46.1% of patients and endocrine therapy for 28.9% of patients. The median brain-specific (bs) progression-free survival (PFS) was 7 months (95% CI: 5.2 – 9) and median overall survival (OS) was 10 months (95% CI: 8.5 – 13.4). In subgroup analyses, bsPFS (5 months versus 11 months, p<0.001) and OS (7.3 versus 20.7 months, p<0.001) were significantly shorter among patients with endocrine resistant breast cancer than those with endocrine sensitive disease.

CONCLUSIONS

Patients with HR+/HER2- BCBrM have poor outcomes. A substantial proportion of patients with endocrine resistant disease have particularly short bsPFS and OS, highlighting the need for novel systemic treatment approaches with efficacy in the brain.
==== Body
pmc
